The FDA cleared ORTHOReBIRTH USA's ReBOSSIS. ORTHOReBIRTH develops orthopedic biologics.
Here are five highlights:
1. ReBOSSIS is the sole biosynthetic bone scaffold with electrospun microfiber construction.
2. The product is designed for posterolateral spine procedures.
3. ReBOSSIS has yielded a 54 percent compression recovery rate.
4. Providers have used ReBOSSIS in more than 1,500 procedures.
5. ORTHOReBIRTH USA is a wholly owned subsidiary of ORTHOReBIRTH Co.